Risk factors for haematopoietic stem cell transplant (HSCT) associated bone loss

BONE MARROW TRANSPLANTATION (BMT) also called haematopoietic stem cell transplant (HSCT) is the treatment of choice for many haematological diseases including haematological malignancies and different types of anaemia1. The number of HSCT is increasing every year, mainly because of advanced research that has allowed an expansion in the number of indications for which it has become the first-line therapy2. The long-term survival of patients that have undergone BMT continues to improve with several advances in transplantation techniques and supportive care practices.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research